{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:21:54Z","timestamp":1793305314572,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T00:00:00Z","timestamp":1672704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ejpb.2023.01.001","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T10:21:47Z","timestamp":1674037307000},"page":"103-115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Comprehensive physicochemical characterization of a peptide-based medicine: Teduglutide (Revestive\u00ae) structural description and stress testing"],"prefix":"10.1016","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4811-9409","authenticated-orcid":false,"given":"Raquel","family":"P\u00e9rez-Robles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Salmer\u00f3n-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2390-2360","authenticated-orcid":false,"given":"Jesus","family":"Hermosilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2507-6760","authenticated-orcid":false,"given":"Anabel","family":"Torrente-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6272-6438","authenticated-orcid":false,"given":"Susana","family":"Clemente-Bautista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4473-6768","authenticated-orcid":false,"given":"In\u00e9s","family":"Jim\u00e9nez-Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Josep","family":"Caba\u00f1as-Poy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Cabeza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2536-1430","authenticated-orcid":false,"given":"Natalia","family":"Navas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2023.01.001_b0005","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40265-017-0703-7","article-title":"Teduglutide: a review in short bowel syndrome","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs."},{"key":"10.1016\/j.ejpb.2023.01.001_b0010","doi-asserted-by":"crossref","unstructured":"C.B. Burness, P.L. Mccormack, Teduglutide: A review of its use in the treatment of patients with short bowel syndrome, 2013, pp. 935\u2013947.","DOI":"10.1007\/s40265-013-0070-y"},{"key":"10.1016\/j.ejpb.2023.01.001_b0015","unstructured":"EMEA\/H\/C\/002345\/, European Public Assessment Report (EPAR) Summary for Revestive, Annex I: Summary of Product Characteristics, European Medicines Agency (EMA), London (UK), 2012."},{"key":"10.1016\/j.ejpb.2023.01.001_b0020","first-page":"1","article-title":"A comprehensive review on current advances in peptide drug development and design","volume":"20","author":"Lee","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2023.01.001_b0025","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/jpen.1588","article-title":"Impact of teduglutide on quality of life among patients with short bowel syndrome and intestinal failure","volume":"44","author":"Chen","year":"2020","journal-title":"J. Parenter. Enter. Nutr."},{"key":"10.1016\/j.ejpb.2023.01.001_b0030","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1016\/j.bmc.2017.06.052","article-title":"Therapeutic peptides: Historical perspectives, current development trends, and future directions","volume":"26","author":"Lau","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejpb.2023.01.001_b0035","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.xphs.2017.02.029","article-title":"Potential issues with the handling of biologicals in a hospital","volume":"106","author":"Jiskoot","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.01.001_b0040","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.xphs.2018.04.005","article-title":"Postproduction handling and administration of protein pharmaceuticals and potential instability issues","volume":"107","author":"Nejadnik","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.01.001_b0045","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1016\/j.xphs.2019.06.004","article-title":"forced degradation of monoclonal antibodies after compounding: impact on routine hospital quality control","volume":"108","author":"Jaccoulet","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.01.001_b0050","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1208\/s12248-014-9688-2","article-title":"Physicochemical and formulation developability assessment for therapeutic peptide delivery\u2014a primer","volume":"17","author":"Bak","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2023.01.001_b0055","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejps.2009.06.001","article-title":"Structural properties of monoclonal antibody aggregates induced by freeze\u2013thawing and thermal stress","volume":"38","author":"Hawe","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.01.001_b0060","doi-asserted-by":"crossref","first-page":"25134","DOI":"10.1074\/jbc.M110.160440","article-title":"chemical modifications in therapeutic protein aggregates generated under different stress conditions","volume":"286","author":"Luo","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejpb.2023.01.001_b0065","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide therapeutics: current status and future directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2023.01.001_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2004.11.014","article-title":"Protein aggregation and its inhibition in biopharmaceutics","volume":"289","author":"Wang","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.01.001_b0075","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1080\/19420862.2017.1368602","article-title":"Forced degradation of recombinant monoclonal antibodies: A practical guide","volume":"9","author":"Nowak","year":"2017","journal-title":"MAbs."},{"key":"10.1016\/j.ejpb.2023.01.001_b0080","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejpb.2015.10.016","article-title":"Forced degradation studies of biopharmaceuticals: Selection of stress conditions","volume":"98","author":"Tamizi","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2023.01.001_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.115064","article-title":"Tracking the physicochemical stability of teduglutide (Revestive\u00ae) clinical solutions over time in different storage containers","volume":"221","author":"P\u00e9rez-Robles","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejpb.2023.01.001_b0090","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1039\/D2AY01254E","article-title":"Method for identification and quantification of intact teduglutide peptide using (RP)UHPLC-UV-(HESI\/ORBITRAP)MS","volume":"14","author":"P\u00e9rez-Robles","year":"2022","journal-title":"Anal. Methods."},{"key":"10.1016\/j.ejpb.2023.01.001_b0095","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.xphs.2019.06.028","article-title":"The glucagon-like peptide 2 analog teduglutide reversibly associates to form pentamers","volume":"109","author":"Philo","year":"2020","journal-title":"J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.ejpb.2023.01.001_b0100","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1080\/19420862.2016.1189048","article-title":"A comparison of biophysical characterization techniques in predicting monoclonal antibody stability","volume":"8","author":"Thiagarajan","year":"2016","journal-title":"Mabs"},{"key":"10.1016\/j.ejpb.2023.01.001_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-59465-7","article-title":"Comprehensive biophysical and functional study of ziv-aflibercept: characterization and forced degradation","volume":"10","author":"Hermosilla","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejpb.2023.01.001_b0110","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/nar\/gkh371","article-title":"DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data","volume":"1","author":"Whitmore","year":"2004","journal-title":"Nucleic Acids Research."},{"key":"10.1016\/j.ejpb.2023.01.001_b0115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/pro.4153","article-title":"DichroWeb, a website for calculating protein secondary structure from circular dichroism spectroscopic data","volume":"31","author":"Miles","year":"2021","journal-title":"Protein Science"},{"key":"10.1016\/j.ejpb.2023.01.001_b0120","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0003-2697(86)90241-1","article-title":"Analysis of protein circular dichroism spectra for secondary structure using a simple matrix multiplication","volume":"155","author":"Compton","year":"1986","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejpb.2023.01.001_b0125","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1021\/bi00504a006","article-title":"Estimation of Globular Protein Secondary Structure from Circular Dichroism","volume":"20","author":"Provencher","year":"1981","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejpb.2023.01.001_b0130","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/bioinformatics\/btl327","article-title":"A reference database for circular dichroism spectroscopy covering fold and secondary structure space","volume":"22","author":"Lees","year":"2006","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ejpb.2023.01.001_b0135","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/bip.20853","article-title":"Protein secondary structure analyses from circular dichroism spectroscopy: Methods and reference databases","volume":"89","author":"Whitmore","year":"2008","journal-title":"Biopolymers"},{"key":"10.1016\/j.ejpb.2023.01.001_b0140","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0165-9936(98)00112-5","article-title":"Applications of circular dichroism in protein and peptide analysis, TrAC","volume":"18","author":"Greenfield","year":"1999","journal-title":"Trends Anal. Chem."},{"issue":"1","key":"10.1016\/j.ejpb.2023.01.001_b0145","first-page":"2876","article-title":"Using circular dichroism spectra to estimate protein secondary structure","volume":"16","author":"Greenfield","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejpb.2023.01.001_b0150","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ejps.2018.01.022","article-title":"Peptide drug stability: The anti-inflammatory drugs Pep19-2.5 and Pep19-4LF in cream formulation","volume":"115","author":"Kuhlmann","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.01.001_b0155","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1007\/s00216-018-0848-6","article-title":"Development of an LC-MS\/MS peptide mapping protocol for the NISTmAb","volume":"410","author":"Mouchahoir","year":"2018","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.ejpb.2023.01.001_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2019.121895","article-title":"Development of an efficient LC-MS peptide mapping method using accelerated sample preparation for monoclonal antibodies","volume":"1137","author":"Jiang","year":"2020","journal-title":"J. Chromatogr. B."},{"key":"10.1016\/j.ejpb.2023.01.001_b0165","doi-asserted-by":"crossref","first-page":"7035","DOI":"10.3390\/ijms21197035","article-title":"Mechanisms of deamidation of asparagine residues and effects of main-chain conformation on activation energy","volume":"21","author":"Kato","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2023.01.001_b0170","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/j.xphs.2022.05.005","article-title":"Investigation of immune responses to oxidation, deamidation, and isomerization in therapeutic antibodies using preclinical immunogenicity risk assessment assays","volume":"111","author":"Zeunik","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.01.001_b0175","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00726-019-02787-2","article-title":"Susceptibility of protein therapeutics to spontaneous chemical modifications by oxidation, cyclization, and elimination reactions","volume":"51","author":"Grassi","year":"2019","journal-title":"Amino Acids."},{"key":"10.1016\/j.ejpb.2023.01.001_b0180","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejpb.2018.02.007","article-title":"Protection of therapeutic antibodies from visible light induced degradation: Use safe light in manufacturing and storage","volume":"127","author":"Du","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2023.01.001_b0185","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1038\/s41422-020-00442-0","article-title":"A unique hormonal recognition feature of the human glucagon-like peptide-2 receptor","volume":"30","author":"Sun","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.ejpb.2023.01.001_b0190","unstructured":"PudChem,WWW.pubchem.ncbi.nlm.nih.gov\/compound\/Teduglutide#section=Structures (Accessed May 2022)."},{"key":"10.1016\/j.ejpb.2023.01.001_b0195","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ijbiomac.2018.06.105","article-title":"Study of aggregation in therapeutic monoclonal antibodies subjected to stress and long-term stability tests by analyzing size exclusion liquid chromatographic profiles","volume":"118","author":"Hern\u00e1ndez-Jim\u00e9nez","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejpb.2023.01.001_b0205","doi-asserted-by":"crossref","first-page":"20170030","DOI":"10.1098\/rsfs.2017.0030","article-title":"Factors affecting the physical stability (aggregation) of peptide therapeutics","volume":"7","author":"Zapadka","year":"2017","journal-title":"Interface Focus."},{"key":"10.1016\/j.ejpb.2023.01.001_b0210","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.xphs.2016.01.012","article-title":"The Effects of Light-Accelerated Degradation on the Aggregation of Marketed Therapeutic Monoclonal Antibodies Evaluated by Size-Exclusion Chromatography With Diode Array Detection","volume":"105","author":"Hern\u00e1ndez-Jim\u00e9nez","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.01.001_b0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11095-020-2763-8","article-title":"Photo-Degradation of Therapeutic Proteins: Mechanistic Aspects","volume":"37","author":"Sch\u00f6neich","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2023.01.001_b0217","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/jmr.2154","article-title":"The dimerization of glucagon-like peptide-2 MIMETIBODYTM is linked to leucine-17 in the glucagon-like peptide-2 region","volume":"25","author":"Baker","year":"2012","journal-title":"J. Mol. Recognit."},{"key":"10.1016\/j.ejpb.2023.01.001_b0219","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.febslet.2010.12.011","article-title":"Conformational and molecular interaction studies of glucagon-like peptide-2 with its N-terminal extracellular receptor domain","volume":"585","author":"Venneti","year":"2011","journal-title":"FEBS Letters."},{"key":"10.1016\/j.ejpb.2023.01.001_b0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19420862.2020.1783062","article-title":"An evaluation of instrument types for mass spectrometry-based multi-attribute analysis of biotherapeutics","volume":"12","author":"Zhang","year":"2020","journal-title":"MAbs"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123000012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123000012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:50:57Z","timestamp":1760547057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641123000012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":45,"alternative-id":["S0939641123000012"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.01.001","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive physicochemical characterization of a peptide-based medicine: Teduglutide (Revestive\u00ae) structural description and stress testing","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}